Shots:

• The P-III (GMMG-HD7) trial assessed Sarclisa (10mg/kg, IV, QW for 1st cycle then biweekly during induction) + lenalidomide, bortezomib & dexamethasone (RVd) vs RVd in transplant-eligible NDMM (n=662), with patients receiving three 42-day cycles of RVd, with Sarclisa added in one arm (part 1) & either Sarclisa + lenalidomide or lenalidomide alone for maintenance post-transplant (part 2)
• Results showed extended PFS with the combination leading to a reduction in disease progression or death. Full data will be highlighted at future conferences
• Sarclisa, a monoclonal antibody, works by targeting the CD38 receptor on multiple myeloma cells, producing antitumor activity through the mechanisms of apoptosis and immunomodulation